Evidence map›Paper›PMID 37976160›Full record

ArticleCell reports2023

Abundant binary promoter switches in lineage-determining transcription factors indicate a digital component of cell fate determination.

Hongchuan Li, Md Ahasanur Rahman, Michael Ruesch, Caprice D Eisele, Erik M Anderson, Paul W Wright, Jennie Cao, Shashikala Ratnayake, Qingrong Chen, Chunhua Yan and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Hongchuan LiBasic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Md Ahasanur RahmanCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Michael RueschBiomedical Sciences Graduate Program, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; Medical Scientist Training Program, The Ohio State University, Columbus, OH 43210, USA.
Caprice D EiseleBiomedical Sciences Graduate Program, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Erik M AndersonCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Paul W WrightBasic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Jennie CaoCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Shashikala RatnayakeCancer Genomics and Bioinformatics Branch, Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD 20892, USA.
Qingrong ChenCancer Genomics and Bioinformatics Branch, Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD 20892, USA.
Chunhua YanCancer Genomics and Bioinformatics Branch, Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD 20892, USA.
Daoud MeerzamanCancer Genomics and Bioinformatics Branch, Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD 20892, USA.
Roshini S AbrahamDepartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH 43210, USA; Department of Pathology, The Ohio State University, Columbus, OH 43210, USA.
Aharon G FreudDepartment of Pathology, The Ohio State University, Columbus, OH 43210, USA.
Stephen K AndersonBasic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA. Electronic address: andersonst@nih.gov.
National Cancer Institute · USFrederick National Laboratory for Cancer Research · USThe Ohio State University · USNationwide Children's Hospital · US

Funding

Molecular Studies of Cellular CytotoxicityZIABC010013 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ANDERSON, STEPHEN K · 2009 to 2025
$17.2M
Elucidation of Human Natural Killer Cell DevelopmentR01CA208353 · NCI · OHIO STATE UNIVERSITY · PI AHARON G FREUD · 2017 to 2026
$4.0M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC010013NCI NIH HHS HHSN261200800001ENCI NIH HHS L30 CA199447NCI NIH HHS R01 CA208353
6 · The paper itself

Abstract

Previous studies of the murine Ly49 and human KIR gene clusters implicated competing sense and antisense promoters in the control of variegated gene expression. In the current study, an examination of transcription factor genes defines an abundance of convergent and divergent sense/antisense promoter pairs, suggesting that competing promoters may control cell fate determination. Differentiation of CD34

Indexed as

GATA1 Transcription FactorTranscription FactorsAnimalsCell DifferentiationGATA2 Transcription FactorHumansMicePromoter Regions, GeneticGATA1 Transcription FactorGATA2 Transcription FactorTranscription FactorsAHRantisense transcriptioncell differentiationCP: Molecular biologyCP: Stem cell researchdivergent/convergent transcriptionGATA1GATA2lineage determiningRORCtranscription factors

Identifiers

PMID37976160
PMCPMC10842785
OpenAlexW4388745390

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.